Using Circulating Tumor DNA for Colon Cancer Adjuvant Therapy: To Be or Not to Be?
Where this comes from
- Record sourced from PubMed, PMID 34848532.
- Also identified by DOI 10.1158/1078-0432.CCR-21-3564.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Detection of circulating tumor DNA (ctDNA) postoperatively is prognostic for recurrence for patients with stage III colon cancer. Those with sustained undetectable ctDNA will likely be cured. Eradication of minimal residual disease (per ctDNA clearance) with chemotherapy did not occur in most ctDNA-positive patients and led to eventual disease relapse.<i>See related article by Henriksen et al., p. 507</i>.
Medical subject headings
- Circulating Tumor DNA
- Colonic Neoplasms